# VyBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vybio

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.vybio.com
- Latest round: Series B (Nov 13, 2025)
- Investors on record: 2

## About

Established in 2018 and based in Hangzhou, China, Zhejiang Yangli Pharmaceutical Technology Co., Ltd., trading under VyBio or VyBio Therapeutics, operates as a pharmaceutical research and development company focusing on innovative drug discovery. Since inception, the company has centered its research pipeline on first-in-class and best-in-class therapeutics addressing oncology and chronic disease indications. Its founding and core scientific team includes drug discovery and clinical development specialists educated at institutions such as Tsinghua University, the University of California Los Angeles, the State University of New York, Sichuan University West China Medical Center and the University of Hong Kong. In November 2025, the firm closed a series B funding round from Qiming Ventures Partners.

The company’s pipeline consists of novel therapeutic candidates targeting oncology and chronic disease treatment needs, several of which have entered Phase I and Phase II clinical trials. Its research activities include early-stage discovery, preclinical evaluation, and clinical development of drug candidates with global intellectual property protection.

The company generates revenue primarily through pharmaceutical development activities, which include partnerships, licensing agreements, and collaboration with industry partners.

The company plans to expand its pipeline for oncology and chronic diseases, accelerate ongoing clinical programs and enhance its capacity for global-standard clinical development.

## Funding rounds

- Series B, Nov 13, 2025 — Qiming Venture Partners
- Series B, Jun 26, 2023 — Winfast Holding

## Investors

- Winfast Holding (https://capitalatlas.ai/funds/winfast-holding) — Series B
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Series B